Product DNN.65.21.005 not checked
Ache Laboratorios Farmaceuticos S.A.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Prostatic Hyperplasia, Benign
- Main trialPhase 3
- “To evaluate the safety and efficacy of DNN.65.21.005 versus Combodart® in the treatment of benign prostatic hyperplasia”In the company’s words, NCT07270432 on ClinicalTrials.gov
Other drugs for Prostatic Hyperplasia, Benign
- H077 sustained-releaseShanghai Huilun Pharmaceutical Co., Ltd. · Phase 3
- FinasterideIl-Yang Pharm. Co., Ltd. · Phase 3
- TamsulosinIl-Yang Pharm. Co., Ltd. · Phase 3
- DTT106EMS · Phase 3
- Teverelix DPAntev Ltd. · Phase 2
- RT-310Resurge Therapeutics Inc. · Phase 2
Coming up1
- Apr 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Apr 2027 | Efficacy/ Safety of Product DNN.65.21.005 in Patients With Benign Prostatic Hyperplasia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026